Mit and Recursion unveil Boltz-2 to speed up drug discovery

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

MIT and Recursion have released Boltz-2, a next-generation artificial intelligence model designed to predict the binding affinity between molecules and protein targets with what the companies describe as “unprecedented” speed, scale, and accuracy.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Windward Bio raises $251m with Sanofi buying in

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE